Fabispray – Temporarily not in stock


Fabispray is a patented formulation that has won approval as an early treatment option for Covid-19 and Covid prevention in the future.

India Corporation Glenmark and its Canadian partners Sanotize Research announces the release of Fabispray (Nitric Oxide Spray) for the treatment of adult patients at high risk for SARs or Cov-2. Sanotize Research and Development is a rapidly growing pharmaceutical company and are pioneers in nitric oxide technology and therapeutic research.

Phase III clinical trials demonstrated a 99% viral load reduction in just 48 hours.


There are no reviews yet.

Only logged in customers who have purchased this product may leave a review.

Shopping Cart
Scroll to Top